Cardiology Today

22/10/2025

Approval of oral semaglutide (Rybelsus) for prevention of CV events was based on the positive results of the SOUL trial presented at the American College of Cardiology Scientific Session and published in The New England Journal of Medicine. Read more: https://www.healio.com/news/cardiology/20251020/rybelsus-becomes-first-oral-glp1-approved-for-cvd-prevention-in-adults-with-diabetes

22/10/2025

💊Progressive antihypertensive drug discontinuation did not lower risk for mortality among older nursing home residents with frailty.

👇Read more from the RETREAT-FRAIL trial below

If you would like to edit or change the email address that your subscriptions and alerts are sent to, use the "Update email address" link.

22/10/2025

🗣️ “We can use this to systematically influence the body, which will hopefully push forward the use of music in cardiovascular therapies,” Natalia Cotic, PhD student at said at

Music with more predictability was shown to “entrain” listeners’ blood pressure, suggesting music-based BP modulation strategies could benefit patients with hypertension or autonomic dysfunction, a speaker reported.The results of the HeartFM study on the impact of musical phrase ar...

21/10/2025

⚠️ From ⚠️

GLP-1s may confer greater protection from major adverse cardiovascular events compared with sulfonylureas, DPP-IV inhibitors and SGLT2 inhibitors for patients with type 2 diabetes.

GLP-1s may confer greater protection from major adverse cardiovascular events compared with sulfonylureas, dipeptidyl-peptidase IV inhibitors and SGLT2 inhibitors in patients with type 2 diabetes, researchers reported.The protective effects of GLP-1s were especially pronounced among adults aged 65 y...

21/10/2025

Heart disease remains the leading cause of death for women worldwide, but women have been historically underrepresented in cardiovascular clinical trials.
New research shows recent progress, but barriers remain.

Heart disease remains the leading cause of death for women worldwide, but women have historically been underrepresented in cardiovascular clinical trials. Progress has been made in the past decade, but persistent gaps remain, data show.Representation of women in CV trials continues to vary by type o...

20/10/2025

⚠️ Also from ⚠️

Music with more predictability was shown to ‘entrain’ listeners’ blood pressure, suggesting music-based BP modulation strategies could benefit patients with hypertension or autonomic dysfunction, a speaker reported.

Music with more predictability was shown to “entrain” listeners’ blood pressure, suggesting music-based BP modulation strategies could benefit patients with hypertension or autonomic dysfunction, a speaker reported.The results of the HeartFM study on the impact of musical phrase ar...

20/10/2025

update

Novo Nordisk announced the FDA approved for reducing risk for the primary or secondary prevention of major adverse cardiovascular events in high-risk adults with type 2
https://www.healio.com/news/cardiology/20251020/rybelsus-becomes-first-oral-glp1-approved-for-cvd-prevention-in-adults-with-diabetes

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide (Rybelsus), which covers both the primary and secondary CVD prevention populations, was based on the positiv...

20/10/2025

Bringing a biosimilar to market isn’t just about science, it’s about legal strategy.

💥 Patent lawsuits, exclusivity periods and courtroom showdowns slow the rollout of more affordable options.
From Sandoz v. Amgen to Humira’s 100+ patents, biosimilar makers often face a legal maze known as the “patent dance.”

🧠 Learn how this complex process shapes drug pricing and delays access in Biosimilars: A Healio® Guide for Clinicians: https://bit.ly/4ltP5vx

19/10/2025

Data from the show the impact long-term exposure to high may have on and cognitive decline. Read more: https://www.healio.com/news/cardiology/20251017/lifetime-exposure-to-high-blood-pressure-linked-to-cognitive-decline-dementia

Cumulative exposure to high blood pressure from childhood to young adulthood may impact development of cognitive disorders at midlife, researchers reported.Data from an analysis of the Bogalusa Heart Study, a long-term CV epidemiology study in a rural population in Bogalusa, Louisiana, were publishe...

18/10/2025

📣 “Besides being effective, LUCAS 3 should be considered for CPR in spaceflight because it has secondary benefits,” Nathan Reynette of the University Hospital of Nancy said at

Performing chest compressions in zero gravity is complicated, but a standard mechanical piston device stored aboard a space vessel could deliver CPR on par with current international guidelines, a speaker reported.Manual methods of CPR for cardiac arrest in microgravity environments have been previo...

17/10/2025

🩺From 🩺

Cumulative exposure to high blood pressure from childhood to young adulthood may impact development of cognitive disorders at midlife.

Cumulative exposure to high blood pressure from childhood to young adulthood may impact development of cognitive disorders at midlife, researchers reported.Data from an analysis of the Bogalusa Heart Study, a long-term CV epidemiology study in a rural population in Bogalusa, Louisiana, were publishe...

17/10/2025

Joakim Nordanstig, MD, PhD at : “Mortality was an issue with paclitaxel-coated devices in a meta-analysis back in 2018 ... It’s hard for us to ignore the fact that it seems we mirrored that signal in SWEDEPAD 2 but not in SWEDEPAD 1.”

Paclitaxel-coated vs. uncoated devices did not reduce amputations in patients with chronic limb-threatening ischemia and raised risk for mortality at 5 years in patients with intermittent claudication, researchers reported. The SWEDEPAD 1 study of drug-coated devices vs. uncoated devices in patients...